Overview of the genetic determinants of primary aldosteronism

Application of Clinical Genetics

Volumn 7, Issue , 2014, Pages 67-79

  Al Salameh, Abdallah ^a   Cohen, Régis ^b   Desailloud, Rachel ^c  

^a Centre Hospitalier de Creil   (France)

^b Centre Hospitalier de Saint Denis   (France)

^c AMIENS UNIVERSITY HOSPITAL   (France)

Author keywords

Potassium channels; Primary aldosteronism; Secondary hypertension

Indexed keywords

ADRENAL CELL; ADRENAL HYPERPLASIA; ATP1A1 GENE; ATP2B3 GENE; CACNA1D GENE; CALCIUM CELL LEVEL; CELL PROLIFERATION; FAMILIAL HYPERALDOSTERONISM TYPE I; FAMILIAL HYPERALDOSTERONISM TYPE II; FAMILIAL HYPERALDOSTERONISM TYPE III; GAIN OF FUNCTION MUTATION; GENE; GENE MUTATION; GENOTYPE PHENOTYPE CORRELATION; GLOMERULOSA CELL; HUMAN; HYPERALDOSTERONISM; KCNJ5 GENE; PRIMARY HYPERALDOSTERONISM; REVIEW; SOMATIC MUTATION;

EID: 84898750773     PISSN: None     EISSN: 1178704X     Source Type: Journal    
DOI: 10.2147/TACG.S45620     Document Type: Review

References (60)

1. Funder JW, Carey RM, Fardella C, et al; Endocrine Society. Case detection, diagnosis, and treatment of patients with primary aldosteronism: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2008;93(9):3266-3281.
2. Rossi GP, Seccia TM, Pessina AC. Primary aldosteronism: part II: subtype differentiation and treatment. J Nephrol. 2008;21(4):455-462.
3. Funder JW. The genetics of primary aldosteronism: chapter two. Hypertension. 2012;59(3):537-538.
4. Conn JW. Presidential address. I. Painting background. II. Primary aldosteronism, a new clinical syndrome. J Lab Clin Med. 1955;45(1):3-17.
5. Rossi GP, Bernini G, Caliumi C, et al; PAPY Study Investigators. A prospective study of the prevalence of primary aldosteronism in 1,125 hypertensive patients. J Am Coll Cardiol. 2006;48(11):2293-2300.
6. Rossi GP, Seccia TM, Pessina AC. Primary aldosteronism - part I: prevalence, screening, and selection of cases for adrenal vein sampling. J Nephrol. 2008;21(4):447-454.
7. Fagugli RM, Taglioni C. Changes in the perceived epidemiology of primary hyperaldosteronism. Int J Hypertens. 2011;2011:162804.
8. Amar L, Plouin PF, Steichen O. Aldosterone-producing adenoma and other surgically correctable forms of primary aldosteronism. Orphanet J Rare Dis. 2010;5:9.
9. Mosso L, Carvajal C, González A, et al. Primary aldosteronism and hypertensive disease. Hypertension. 2003;42(2):161-165.
10. Zennaro MC. Primary aldosteronism takes (KCNJ) five! Endocrinology. 2012;153(4):1575-1577.
11. Milliez P, Girerd X, Plouin PF, Blacher J, Safar ME, Mourad JJ. Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. J Am Coll Cardiol. 2005;45(8):1243-1248.
12. Stowasser M. Update in primary aldosteronism. J Clin Endocrinol Metab. 2009;94(10):3623-3630.
13. Mulatero P, Monticone S, Bertello C, et al. Long-term cardio- and cerebrovascular events in patients with primary aldosteronism. J Clin Endocrinol Metab. 2013;98(12):4826-4833.
14. Young WF. Primary aldosteronism: renaissance of a syndrome. Clin Endocrinol (Oxf). 2007;66(5):607-618.
15. Choi M, Scholl UI, Yue P, et al. K+ channel mutations in adrenal aldosterone-producing adenomas and hereditary hypertension. Science. 2011;331(6018):768-772.
16. McMahon GT, Dluhy RG. Glucocorticoid-remediable aldosteronism. Arq Bras Endocrinol Metabol. 2004;48(5):682-686.
17. Carey RM. Role of K(+) channels in the pathophysiology of primary aldosteronism. Hypertension. 2012;59(3):534-536.
18. Velarde-Miranda C, Gomez-Sanchez EP, Gomez-Sanchez CE. Regulation of aldosterone biosynthesis by the Kir3.4 (KCNJ5) potassium channel. Clin Exp Pharmacol Physiol. 2013;40(12):895-901.
19. Hattangady NG, Olala LO, Bollag WB, Rainey WE. Acute and chronic regulation of aldosterone production. Mol Cell Endocrinol. 2012;350(2):151-162.
20. Beuschlein F. Regulation of aldosterone secretion: from physiology to disease. Eur J Endocrinol. 2013;168(6):R85-R93.
21. Guagliardo NA, Yao J, Hu C, Barrett PQ. Minireview: aldosterone biosynthesis: electrically gated for our protection. Endocrinology. 2012;153(8):3579-3586.
22. Bassett MH, Suzuki T, Sasano H, White PC, Rainey WE. The orphan nuclear receptors NURR1 and NGFIB regulate adrenal aldosterone production. Mol Endocrinol. 2004;18(2):279-290.
23. Gomez-Sanchez CE, Gomez-Sanchez EP. Mutations of the potassium channel KCNJ5 causing aldosterone-producing adenomas: one or two hits? Hypertension. 2012;59(2):196-197.
24. Yang Y, Yang Y, Liang B, et al. Identification of a Kir3.4 mutation in congenital long QT syndrome. Am J Hum Genet. 2010;86(6):872-880.
25. Monticone S, Hattangady NG, Nishimoto K, et al. Effect of KCNJ5 mutations on gene expression in aldosterone-producing adenomas and adrenocortical cells. J Clin Endocrinol Metab. 2012;97(8): E1567-E1572.
26. Williams TA, Monticone S, Crudo V, Warth R, Veglio F, Mulatero P. Visinin-like 1 is upregulated in aldosterone-producing adenomas with KCNJ5 mutations and protects from calcium-induced apoptosis. Hypertension. 2012;59(4):833-839.
27. Mulatero P, Tauber P, Zennaro MC, et al. KCNJ5 mutations in European families with nonglucocorticoid remediable familial hyperaldosteronism. Hypertension. 2012;59(2):235-240.
28. Azizan EA, Murthy M, Stowasser M, et al. Somatic mutations affecting the selectivity filter of KCNJ5 are frequent in 2 large unselected collections of adrenal aldosteronomas. Hypertension. 2012;59(3): 587-591.
29. Åkerström T, Crona J, Delgado Verdugo A, et al. Comprehensive re-sequencing of adrenal aldosterone producing lesions reveal three somatic mutations near the KCNJ5 potassium channel selectivity filter. PLoS One. 2012;7(7):e41926.
30. Azizan EA, Poulsen H, Tuluc P, et al. Somatic mutations in ATP1A1 and CACNA1D underlie a common subtype of adrenal hypertension. Nat Genet. 2013;45(9):1055-1060.
31. Williams TA, Monticone S, Schack VR, et al. Somatic ATP1A1, ATP2B3, and KCNJ5 Mutations in Aldosterone-Producing Adenomas. Hypertension. 2014;63(1):188-195.
32. Boulkroun S, Beuschlein F, Rossi GP, et al. Prevalence, clinical, and molecular correlates of KCNJ5 mutations in primary aldosteronism. Hypertension. 2012;59(3):592-598.
33. Stowasser M. Primary aldosteronism and potassium channel mutations. Curr Opin Endocrinol Diabetes Obes. 2013;20(3):170-179.
34. Xekouki P, Hatch MM, Lin L, et al. KCNJ5 mutations in the National Institutes of Health cohort of patients with primary hyperaldosteronism: an infrequent genetic cause of Conn's syndrome. Endocr Relat Cancer. 2012;19(3):255-260.
35. Taguchi R, Yamada M, Nakajima Y, et al. Expression and mutations of KCNJ5 mRNA in Japanese patients with aldosterone-producing adenomas. J Clin Endocrinol Metab. 2012;97(4):1311-1319.
36. Zennaro MC, Jeunemaitre X, Boulkroun S. Integrating genetics and genomics in primary aldosteronism. Hypertension. 2012;60(3): 580-588.
37. Al-Salameh A, Cohen R, Chanson P, Plouin PF. [Update on endocrine hypertension]. Ann Endocrinol (Paris). 2012;73 Suppl 1:S26-S35. French.
38. Azizan EA, Lam BY, Newhouse SJ, et al. Microarray, qPCR, and KCNJ5 sequencing of aldosterone-producing adenomas reveal differences in genotype and phenotype between zona glomerulosa- and zona fasciculata-like tumors. J Clin Endocrinol Metab. 2012;97(5): E819-E829.
39. Boulkroun S, Golib Dzib JF, Samson-Couterie B, et al. KCNJ5 mutations in aldosterone producing adenoma and relationship with adrenal cortex remodeling. Mol Cell Endocrinol. 2013;371(1-2):221-227.
40. Beuschlein F, Boulkroun S, Osswald A, et al. Somatic mutations in ATP1A1 and ATP2B3 lead to aldosterone-producing adenomas and secondary hypertension. Nat Genet. 2013;45(4):440-444, 444e1-2.
41. Kumar Dutta R, Welander J, Brauckhoff M, et al. Complementary somatic mutations in sporadic aldosterone producing adrenal adenomas. Endocr Relat Cancer. 2014;21(1):L1-L4.
42. Baig SM, Koschak A, Lieb A, et al. Loss of Ca(v)1.3 (CACNA1D) function in a human channelopathy with bradycardia and congenital deafness. Nat Neurosci. 2011;14(1):77-84.
43. Scholl UI, Goh G, Stölting G, et al. Somatic and germline CACNA1D calcium channel mutations in aldosterone-producing adenomas and primary aldosteronism. Nat Genet. 2013;45(9):1050-1054.
44. Brown MJ. Ins and outs of aldosterone-producing adenomas of the adrenal: from channelopathy to common curable cause of hypertension. Hypertension. 2014;63(1):24-26.
45. Zennaro MC, Rickard AJ, Boulkroun S. Genetics of mineralocorticoid excess: an update for clinicians. Eur J Endocrinol. 2013;169(1): R15-R25.
46. Sutherland DJ, Ruse JL, Laidlaw JC. Hypertension, increased aldosterone secretion and low plasma renin activity relieved by dexamethasone. Can Med Assoc J. 1966;95(22):1109-1119.
47. McMahon GT, Dluhy RG. Glucocorticoid-remediable aldosteronism. Cardiol Rev. 2004;12(1):44-48.
48. Lifton RP, Dluhy RG, Powers M, et al. A chimaeric 11 beta-hydroxylase/aldosterone synthase gene causes glucocorticoid-remediable aldosteronism and human hypertension. Nature. 1992;355(6357):262-265.
49. Stowasser M, Gordon RD, Tunny TJ, Klemm SA, Finn WL, Krek AL. Familial hyperaldosteronism type II: five families with a new variety of primary aldosteronism. Clin Exp Pharmacol Physiol. 1992;19(5):319-322.
50. Hassan-Smith Z, Stewart PM. Inherited forms of mineralocorticoid hypertension. Curr Opin Endocrinol Diabetes Obes. 2011;18(3):177-185.
51. Mulatero P, Tizzani D, Viola A, et al. Prevalence and characteristics of familial hyperaldosteronism: the PATOGEN study (Primary Aldosteronism in TOrino-GENetic forms). Hypertension. 2011;58(5): 797-803.
52. Geller DS, Zhang J, Wisgerhof MV, Shackleton C, Kashgarian M, Lifton RP. A novel form of human mendelian hypertension featuring nonglucocorticoid-remediable aldosteronism. J Clin Endocrinol Metab. 2008;93(8):3117-3123.
53. Oki K, Plonczynski MW, Luis Lam M, Gomez-Sanchez EP, Gomez-Sanchez CE. Potassium channel mutant KCNJ5 T158A expression in HAC-15 cells increases aldosterone synthesis. Endocrinology. 2012;153(4):1774-1782.
54. Scholl UI, Nelson-Williams C, Yue P, et al. Hypertension with or without adrenal hyperplasia due to different inherited mutations in the potassium channel KCNJ5. Proc Natl Acad Sci U S A. 2012;109(7):2533-2538.
55. Charmandari E, Sertedaki A, Kino T, et al. A novel point mutation in the KCNJ5 gene causing primary hyperaldosteronism and early-onset autosomal dominant hypertension. J Clin Endocrinol Metab. 2012;97(8):E1532-E1539.
56. Monticone S, Hattangady NG, Penton D, et al. A Novel Y152C KCNJ5 Mutation Responsible for Familial Hyperaldosteronism Type III. J Clin Endocrinol Metab. 2013;98(11):E1861-E1865.
57. Scholl UI, Lifton RP. New insights into aldosterone-producing adenomas and hereditary aldosteronism: mutations in the K+ channel KCNJ5. Curr Opin Nephrol Hypertens. 2013;22(2):141-147.
58. Goetz L, Bethel K, Topol EJ. Rebooting cancer tissue handling in the sequencing era: toward routine use of frozen tumor tissue. JAMA. 2013;309(1):37-38.
59. Murthy M, Xu S, Massimo G, et al. Role for germline mutations and a rare coding single nucleotide polymorphism within the KCNJ5 potassium channel in a large cohort of sporadic cases of primary aldosteronism. Hypertension. 2014;63(4):783-789.
60. Li NF, Li HJ, Zhang DL, et al. Genetic variations in the KCNJ5 gene in primary aldosteronism patients from Xinjiang, China. PLoS One. 2013;8(1):e54051.